Akebia Charts Vafseo's Path to Standard of Care, Eyes $1B Market Beyond TDAPA
BOSTON – Akebia Therapeutics (NASDAQ: AKBA) laid out a comprehensive roadmap for its anemia therapy Vafseo and broader kidney disease portfolio at the Leerink Partners Global Healthcare Conference this week. The biopharma firm is navigating a critical transition as a temporary Medicare payment adjustment period ends, aiming to establish Vafseo as a new standard against entrenched treatments.
CEO John Butler framed the company's strategy around three core priorities: the aggressive commercialization of Vafseo (vadadustat), sustained investment in kidney disease pipelines, and disciplined financial management. "We're operating as a commercial-stage company with a pipeline," Butler stated, emphasizing "thoughtful" spending allocation.
Vafseo's Clinical and Economic Pitch
Vafseo, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for anemia in dialysis-dependent chronic kidney disease patients, is challenging erythropoiesis-stimulating agents (ESAs), the long-standing standard. Butler argued Vafseo's mechanism allows for a more gradual hemoglobin increase with fewer target excursions, simplifying management.
He highlighted recent data presentations, including a post-hoc "win odds" analysis from the Phase III INNO2VATE program presented at the American Society of Nephrology meeting. The analysis showed a statistically significant reduction in the composite risk of mortality or hospitalization, findings accepted for publication in a top-tier nephrology journal.
An economic analysis presented at a dialysis conference projected an 8% reduction in hospitalizations and a 16% shorter length of stay with Vafseo, primarily driven by fewer cardiovascular and infection admissions. Using standard Medicare costs, this translates to an estimated $3,700 annual saving per patient. "If all eligible ESA-treated patients switched, the system could see savings approaching $1 billion," Butler noted.
The TIW Dosing Initiative
A central commercial and clinical focus is the push for a three-times-weekly (TIW) dosing regimen. While not yet on the label, Akebia is gathering evidence to support discussions with the FDA. Daily dosing raised adherence concerns as patients historically receive injections during dialysis sessions.
Butler pointed to the ongoing VOICE and VOCAL studies evaluating TIW dosing. He revealed that Dr. Geoffrey Block, an investigator in the VOICE study, has recommended transitioning patients at U.S. Renal Care to TIW, with completion expected this quarter. The 350-patient VOCAL study at DaVita centers could support a regulatory filing for the TIW label.
Navigating the Post-TDAPA Landscape
As the Transitional Drug Add-on Payment Adjustment (TDAPA) period winds down, pricing is expected to converge with ESA levels ($2,000-$2,500 annually). CFO Erik Ostrowski estimated the post-TDAPA market opportunity at roughly $1 billion. Butler acknowledged a likely near-term "divot" in revenue as volume growth initially offsets the pricing shift, but expressed confidence in Vafseo's long-term profitability, especially if it demonstrates cost savings for dialysis providers.
"Achieving a standard-of-care status in a $1 billion market can support a product with $500-plus million in peak sales," Butler reiterated.
Pipeline Beyond Vafseo
Beyond its lead asset, Akebia spotlighted two kidney programs. A Phase II study of praliciguat in focal segmental glomerulosclerosis (FSGS) is enrolling after prior delays. For AKB-097, a tissue-targeted complement inhibitor acquired from Q32 Bio, the company plans an open-label basket study in IgA nephropathy, lupus nephritis, and C3 glomerulopathy in the second half of 2024.
The company will host a virtual R&D day on April 2nd, featuring external key opinion leaders for a deeper pipeline dive.
Market Voices:
"The hospitalization cost data is compelling for dialysis centers, especially those on capitated payments. If the TIW dosing improves real-world adherence as suggested, Vafseo could see rapid uptake post-TDAPA." – Dr. Anya Sharma, Healthcare Portfolio Manager at Horizon Capital.
"The economic argument is strong, but displacing decades of ESA familiarity is a monumental task. Physicians are creatures of habit. Akebia's medical education push with the upcoming journal publication is crucial." – Michael Reed, Biotech Analyst at Clearwater Insights.
"Another 'billion-dollar opportunity' narrative from a company that has consistently overpromised and underdelivered. The TDAPA cliff is real, and this 'divot' they casually mention could be a canyon. Investors should be wary of the hype around early-stage pipeline assets like AKB-097." – David Chen, Founder of Skeptical Biotech Blog.
"The mechanistic sub-study in VOCAL aiming to show Vafseo produces 'more physiologic' red blood cells is fascinating science. If proven, it provides a tangible differentiation beyond just hemoglobin levels, which could be a key marketing tool." – Dr. Lisa Carter, Nephrologist at Metropolitan Hospital.